TriangleAndrogen Receptor Pathway Inhibitor (NCT07466498)
Androgen Receptor Pathway Inhibitor trial for Castration-Sensitive Prostate Adenocarcinoma (NCT07466498). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with new or recurrent metastatic, hormone-sensitive prostate cancer. Prior chemotherapy for hormone-sensitive disease, LHRH therapy and next-generation androgen-receptor treatment are excluded.
The idea: compare estrogen skin patches with usual LHRH hormone therapy. Both groups add an androgen-receptor signaling inhibitor after four weeks to block androgen effects on cancer. Researchers assess hot flashes and quality of life. Severe hot flashes can permit switching to patches after 12 weeks.
This phase 2 study plans 60 patients. Michael Schweizer leads at Fred Hutchinson in Seattle, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.